Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397312

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397312

Autologous Conditioned Plasma Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

PUBLISHED:
PAGES: 314 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

The Autologous Conditioned Plasma Market has experienced remarkable growth, generating global revenue of approximately US$ 590 Million in 2024. The market is poised for continued expansion with a projected Compound Annual Growth Rate (CAGR) of 14%, reaching an estimated valuation of approximately US$ 1519 Million by the end of 2033. Several factors contribute to the growth of the Autologous Conditioned Plasma Market.

Minimally Invasive PRP Therapy Gains Prominence

Platelet-rich plasma (PRP) therapy offers a minimally invasive, efficient, and cost-effective alternative to invasive surgeries. It accelerates tissue regeneration, shortens recovery times, and boasts higher success rates. These advantages are expected to drive the global market for autologous conditioned plasma.

PRP Therapy for Musculoskeletal Injuries

Musculoskeletal injuries are a leading cause of chronic pain and physical disability worldwide, according to the World Health Organization (WHO). PRP therapy has emerged as a promising and appealing alternative to surgery for treating musculoskeletal injuries. Its regenerative capabilities and therapeutic potential make it a preferred choice for clinical settings.

Rising Aging Population Drives Market Growth

Aging populations are more susceptible to soft tissue degeneration, particularly in the knee. Autologous PRP therapy, which involves the use of concentrated platelets from a patient's own blood, has been found effective in treating conditions like knee osteoarthritis. The growing elderly population is expected to further accelerate market growth.

How Can the Global Market Grow?

"Increased FDA Regulatory Approvals and Expanding PRP Application in Sports Medicine to Drive Market Growth"

The Autologous Conditioned Plasma Market is expected to grow significantly due to increased adoption in sports medicine, where injured athletes often seek quick recovery through autologous conditioned plasma therapies. Additionally, the use of autologous conditioned plasma fibrin therapy (P-PRF) is contributing to market growth. P-PRF therapy, a second-generation platelet concentrate, promotes wound healing with growth factors and high platelet content.

Factors Affecting Market Growth:

"Absence of Uniformity in PRP Preparation and Dosage"

One of the challenges in assessing PRP therapy's clinical outcomes is the lack of consistency in dosage, preparation, and platelet-separation techniques. This lack of standardization reduces the ability to generalize research findings, making it challenging to interpret results, which may hinder market growth.

"Lack of Definitive Scientific Evidence"

Although research is ongoing to evaluate PRP therapy's efficacy in orthopedic applications, there is not yet enough scientific evidence to determine the extent of its effectiveness. Doubts about therapy's therapeutic impact on pain management and wound healing may limit market expansion.

Why is the United States Market Booming?

"The Presence of Established Players and High Demand"

The United States market is thriving due to the presence of multiple manufacturing facilities focused on developing innovative PRP-based treatments, high procurement by hospitals and clinics, and the strong presence of major market players. Regulatory support and approvals further bolster the market's presence and are expected to fuel growth.

Will Germany Be a Lucrative Market for Autologous Conditioned Plasma?

Germany's growing emphasis on research and development, constant product development and innovation, and the presence of well-established players make it a promising market for autologous conditioned plasma. The country's support for PRP-based therapies is contributing to market expansion.

How is China Emerging as a Prominent Market?

China is expected to witness high demand for PRP therapies due to its aging population, increasing cases of arthritis, and the use of PRP therapies in cosmetic procedures such as fat grafting, plastic surgeries, and aesthetic skin rejuvenation. The country's expanding research and development in these areas will further drive market growth.

Competitive Landscape:

Key players in the global Autologous Conditioned Plasma Market are focusing on strategic partnerships and intensive research and development to enhance platelet-rich plasma-based therapy options. Acquiring patents for new products is also a growth strategy, enabling companies to lead in the market.

Key Companies Profiled:

  • Zimmer Biomet Inc.
  • Terumo Corporation
  • DePuy Synthes, Inc.
  • AdiStem Ltd.
  • Arthrex, Inc.
  • Stryker Corporation
  • Cesca Therapeutics, Inc.
  • Biotechnology Institute BTI
  • Dr. PRP America LLC
  • EmCyte Corporation
  • Vivostat A/S
  • Regen Lab SA
  • Royal Biologics
  • Exactech, Inc.
  • Platelex S.R.O

Market Segmentation

Composition:

  • Pure Platelet-Rich Plasma (P-PRP)
  • Pure Platelet-Rich Fibrin (P-PRF)
  • Leukocyte- and Platelet-Rich Plasma (LPRP)
  • Leukocyte- and Platelet-Rich Fibrin (L-PRF)

Source:

  • Autologous Platelet-Rich Plasma
  • Allogeneic Platelet-Rich Plasma
  • Homologues Platelet-Rich Plasma

Indication:

  • Skin Ulcer
    • Venous Ulcers
    • Arterial Ulcers
    • Diabetic Foot Ulcers
  • Bone Fractures and Grafts
  • Prostheses Surgeries
  • Oral Implantology
  • Sport Injuries & Trauma
  • Cosmetic Surgery
  • Others

End User:

  • Hospitals
  • Ambulatory Surgical Centre
  • Specialty Clinics
  • Orthopedic & Trauma Centers
  • Research Institutes

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Autologous Conditioned Plasma Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Autologous Conditioned Plasma Market Outlook, 2018 - 2031

  • 3.1. Global Autologous Conditioned Plasma Market Outlook, by Composition, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Pure Platelet-Rich Plasma (P-PRP)
      • 3.1.1.2. Pure Platelet-Rich Fibrin (P-PRF)
      • 3.1.1.3. Leukocyte- and Platelet-Rich Plasma (LPRP)
      • 3.1.1.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
  • 3.2. Global Autologous Conditioned Plasma Market Outlook, by Source, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Autologous Platelet-Rich Plasma
      • 3.2.1.2. Allogeneic Platelet-Rich Plasma
      • 3.2.1.3. Homologues Platelet-Rich Plasma
  • 3.3. Global Autologous Conditioned Plasma Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Skin Ulcer
        • 3.3.1.1.1. Venous Ulcers
        • 3.3.1.1.2. Arterial Ulcers
        • 3.3.1.1.3. Diabetic Foot Ulcers
      • 3.3.1.2. Bone Fractures and Grafts
      • 3.3.1.3. Prostheses Surgeries
      • 3.3.1.4. Oral Implantology
      • 3.3.1.5. Sport Injuries & Trauma
      • 3.3.1.6. Cosmetic Surgery
      • 3.3.1.7. Others
  • 3.4. Global Autologous Conditioned Plasma Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospitals
      • 3.4.1.2. Ambulatory Surgical Centre
      • 3.4.1.3. Specialty Clinics
      • 3.4.1.4. Orthopedic & Trauma Centers
      • 3.4.1.5. Research Institutes
  • 3.5. Global Autologous Conditioned Plasma Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Autologous Conditioned Plasma Market Outlook, 2018 - 2031

  • 4.1. North America Autologous Conditioned Plasma Market Outlook, by Composition, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Pure Platelet-Rich Plasma (P-PRP)
      • 4.1.1.2. Pure Platelet-Rich Fibrin (P-PRF)
      • 4.1.1.3. Leukocyte- and Platelet-Rich Plasma (LPRP)
      • 4.1.1.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
  • 4.2. North America Autologous Conditioned Plasma Market Outlook, by Source, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Autologous Platelet-Rich Plasma
      • 4.2.1.2. Allogeneic Platelet-Rich Plasma
      • 4.2.1.3. Homologues Platelet-Rich Plasma
  • 4.3. North America Autologous Conditioned Plasma Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Skin Ulcer
        • 4.3.1.1.1. Venous Ulcers
        • 4.3.1.1.2. Arterial Ulcers
        • 4.3.1.1.3. Diabetic Foot Ulcers
      • 4.3.1.2. Bone Fractures and Grafts
      • 4.3.1.3. Prostheses Surgeries
      • 4.3.1.4. Oral Implantology
      • 4.3.1.5. Sport Injuries & Trauma
      • 4.3.1.6. Cosmetic Surgery
      • 4.3.1.7. Others
  • 4.4. North America Autologous Conditioned Plasma Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospitals
      • 4.4.1.2. Ambulatory Surgical Centre
      • 4.4.1.3. Specialty Clinics
      • 4.4.1.4. Orthopedic & Trauma Centers
      • 4.4.1.5. Research Institutes
  • 4.5. North America Autologous Conditioned Plasma Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 4.5.1.2. U.S. Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 4.5.1.3. U.S. Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 4.5.1.4. U.S. Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 4.5.1.5. Canada Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 4.5.1.6. Canada Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 4.5.1.7. Canada Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 4.5.1.8. Canada Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Autologous Conditioned Plasma Market Outlook, 2018 - 2031

  • 5.1. Europe Autologous Conditioned Plasma Market Outlook, by Composition, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Pure Platelet-Rich Plasma (P-PRP)
      • 5.1.1.2. Pure Platelet-Rich Fibrin (P-PRF)
      • 5.1.1.3. Leukocyte- and Platelet-Rich Plasma (LPRP)
      • 5.1.1.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
  • 5.2. Europe Autologous Conditioned Plasma Market Outlook, by Source, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Autologous Platelet-Rich Plasma
      • 5.2.1.2. Allogeneic Platelet-Rich Plasma
      • 5.2.1.3. Homologues Platelet-Rich Plasma
  • 5.3. Europe Autologous Conditioned Plasma Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Skin Ulcer
        • 5.3.1.1.1. Venous Ulcers
        • 5.3.1.1.2. Arterial Ulcers
        • 5.3.1.1.3. Diabetic Foot Ulcers
      • 5.3.1.2. Bone Fractures and Grafts
      • 5.3.1.3. Prostheses Surgeries
      • 5.3.1.4. Oral Implantology
      • 5.3.1.5. Sport Injuries & Trauma
      • 5.3.1.6. Cosmetic Surgery
      • 5.3.1.7. Others
  • 5.4. Europe Autologous Conditioned Plasma Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospitals
      • 5.4.1.2. Ambulatory Surgical Centre
      • 5.4.1.3. Specialty Clinics
      • 5.4.1.4. Orthopedic & Trauma Centers
      • 5.4.1.5. Research Institutes
  • 5.5. Europe Autologous Conditioned Plasma Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 5.5.1.2. Germany Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 5.5.1.3. Germany Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.4. Germany Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.5.1.5. U.K. Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 5.5.1.6. U.K. Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 5.5.1.7. U.K. Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.8. U.K. Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.5.1.9. France Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 5.5.1.10. France Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 5.5.1.11. France Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.12. France Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.5.1.13. Italy Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 5.5.1.14. Italy Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 5.5.1.15. Italy Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.16. Italy Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.5.1.17. Turkey Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 5.5.1.18. Turkey Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 5.5.1.19. Turkey Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.20. Turkey Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.5.1.21. Russia Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 5.5.1.22. Russia Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 5.5.1.23. Russia Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.24. Russia Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Autologous Conditioned Plasma Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Autologous Conditioned Plasma Market Outlook, by Composition, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Pure Platelet-Rich Plasma (P-PRP)
      • 6.1.1.2. Pure Platelet-Rich Fibrin (P-PRF)
      • 6.1.1.3. Leukocyte- and Platelet-Rich Plasma (LPRP)
      • 6.1.1.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
  • 6.2. Asia Pacific Autologous Conditioned Plasma Market Outlook, by Source, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Autologous Platelet-Rich Plasma
      • 6.2.1.2. Allogeneic Platelet-Rich Plasma
      • 6.2.1.3. Homologues Platelet-Rich Plasma
  • 6.3. Asia Pacific Autologous Conditioned Plasma Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Skin Ulcer
        • 6.3.1.1.1. Venous Ulcers
        • 6.3.1.1.2. Arterial Ulcers
        • 6.3.1.1.3. Diabetic Foot Ulcers
      • 6.3.1.2. Bone Fractures and Grafts
      • 6.3.1.3. Prostheses Surgeries
      • 6.3.1.4. Oral Implantology
      • 6.3.1.5. Sport Injuries & Trauma
      • 6.3.1.6. Cosmetic Surgery
      • 6.3.1.7. Others
  • 6.4. Asia Pacific Autologous Conditioned Plasma Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospitals
      • 6.4.1.2. Ambulatory Surgical Centre
      • 6.4.1.3. Specialty Clinics
      • 6.4.1.4. Orthopedic & Trauma Centers
      • 6.4.1.5. Research Institutes
  • 6.5. Asia Pacific Autologous Conditioned Plasma Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 6.5.1.2. China Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 6.5.1.3. China Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.4. China Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.5.1.5. Japan Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 6.5.1.6. Japan Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 6.5.1.7. Japan Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.8. Japan Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.5.1.9. South Korea Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 6.5.1.10. South Korea Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 6.5.1.11. South Korea Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.12. South Korea Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.5.1.13. India Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 6.5.1.14. India Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 6.5.1.15. India Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.16. India Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Autologous Conditioned Plasma Market Outlook, 2018 - 2031

  • 7.1. Latin America Autologous Conditioned Plasma Market Outlook, by Composition, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Pure Platelet-Rich Plasma (P-PRP)
      • 7.1.1.2. Pure Platelet-Rich Fibrin (P-PRF)
      • 7.1.1.3. Leukocyte- and Platelet-Rich Plasma (LPRP)
      • 7.1.1.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
  • 7.2. Latin America Autologous Conditioned Plasma Market Outlook, by Source, Value (US$ Mn), 2018 - 2031
      • 7.2.1.1. Autologous Platelet-Rich Plasma
      • 7.2.1.2. Allogeneic Platelet-Rich Plasma
      • 7.2.1.3. Homologues Platelet-Rich Plasma
  • 7.3. Latin America Autologous Conditioned Plasma Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Skin Ulcer
        • 7.3.1.1.1. Venous Ulcers
        • 7.3.1.1.2. Arterial Ulcers
        • 7.3.1.1.3. Diabetic Foot Ulcers
      • 7.3.1.2. Bone Fractures and Grafts
      • 7.3.1.3. Prostheses Surgeries
      • 7.3.1.4. Oral Implantology
      • 7.3.1.5. Sport Injuries & Trauma
      • 7.3.1.6. Cosmetic Surgery
      • 7.3.1.7. Others
  • 7.4. Latin America Autologous Conditioned Plasma Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospitals
      • 7.4.1.2. Ambulatory Surgical Centre
      • 7.4.1.3. Specialty Clinics
      • 7.4.1.4. Orthopedic & Trauma Centers
      • 7.4.1.5. Research Institutes
  • 7.5. Latin America Autologous Conditioned Plasma Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 7.5.1.2. Brazil Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 7.5.1.3. Brazil Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.5.1.4. Brazil Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.5.1.5. Mexico Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 7.5.1.6. Mexico Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 7.5.1.7. Mexico Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.5.1.8. Mexico Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.5.1.9. Argentina Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 7.5.1.10. Argentina Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 7.5.1.11. Argentina Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.5.1.12. Argentina Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Autologous Conditioned Plasma Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Autologous Conditioned Plasma Market Outlook, by Composition, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Pure Platelet-Rich Plasma (P-PRP)
      • 8.1.1.2. Pure Platelet-Rich Fibrin (P-PRF)
      • 8.1.1.3. Leukocyte- and Platelet-Rich Plasma (LPRP)
      • 8.1.1.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
  • 8.2. Middle East & Africa Autologous Conditioned Plasma Market Outlook, by Source, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Autologous Platelet-Rich Plasma
      • 8.2.1.2. Allogeneic Platelet-Rich Plasma
      • 8.2.1.3. Homologues Platelet-Rich Plasma
  • 8.3. Middle East & Africa Autologous Conditioned Plasma Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Skin Ulcer
        • 8.3.1.1.1. Venous Ulcers
        • 8.3.1.1.2. Arterial Ulcers
        • 8.3.1.1.3. Diabetic Foot Ulcers
      • 8.3.1.2. Bone Fractures and Grafts
      • 8.3.1.3. Prostheses Surgeries
      • 8.3.1.4. Oral Implantology
      • 8.3.1.5. Sport Injuries & Trauma
      • 8.3.1.6. Cosmetic Surgery
      • 8.3.1.7. Others
  • 8.4. Middle East & Africa Autologous Conditioned Plasma Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospitals
      • 8.4.1.2. Ambulatory Surgical Centre
      • 8.4.1.3. Specialty Clinics
      • 8.4.1.4. Orthopedic & Trauma Centers
      • 8.4.1.5. Research Institutes
  • 8.5. Middle East & Africa Autologous Conditioned Plasma Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 8.5.1.2. GCC Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 8.5.1.3. GCC Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.5.1.4. GCC Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.5.1.5. South Africa Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 8.5.1.6. South Africa Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 8.5.1.7. South Africa Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.5.1.8. South Africa Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.5.1.9. Egypt Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 8.5.1.10. Egypt Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 8.5.1.11. Egypt Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.5.1.12. Egypt Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.5.1.13. Nigeria Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 8.5.1.14. Nigeria Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 8.5.1.15. Nigeria Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.5.1.16. Nigeria Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Autologous Conditioned Plasma Market by Composition, Value (US$ Mn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Autologous Conditioned Plasma Market by Source, Value (US$ Mn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Autologous Conditioned Plasma Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Autologous Conditioned Plasma Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Composition vs Indication Heatmap
  • 9.2. Manufacturer vs Indication Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Zimmer Biomet Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Terumo Corporation
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. DePuy Synthes, Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. AdiStem Ltd.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Arthrex, Inc.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Stryker Corporation
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Cesca Therapeutics, Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Biotechnology Institute BTI
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Dr. PRP America LLC
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!